Lunning and Abramson Spotlight Developments and Challenges in LBCL Research and Management

Dr Lunning sits down with Jeremy Abramson, MD, to discuss treatment options for patients with LBCL following relapse on their initial therapies, the potential role of surveillance imaging in certain subsets of this population, and the challenging differences that arise when treating patients with cellular therapy in clinical trials vs in the real-world setting.

Lunning Welcomes You to The Blood Club

The Blood Club, hosted by Matthew Lunning, DO, FACP, is a podcast that seeks to translate the latest hematologic oncology research findings into practical clinical implications for the treatment of patients with hematologic malignancies. Dr Lunning is an associate professor in the Division of Oncology & Hematology, associate vice chair of research in the Department of Internal Medicine, and assistant vice chancellor of clinical research at the University of Nebraska Medical Center in Omaha.

In this episode, Dr Lunning sits down with Jeremy Abramson, MD, to discuss updates in relapsed/refractory large B-cell lymphoma (LBCL) research and management. Dr Abramson is the director of the Jon and Jo Ann Hagler Center for Lymphoma at Massachusetts General Hospital, as well as an associate professor of medicine at Harvard Medical School, both in Boston.

Drs Lunning and Abramson highlight treatment options for patients with LBCL following relapse on their initial therapies, the potential role of surveillance imaging in certain subsets of this population, and the challenging differences that arise when treating patients with cellular therapy in clinical trials vs in the real-world setting.